MHRA Halts Tavneos Sales as UniQure Files in Huntington's

The UK's Medicines and Healthcare products Regulatory Agency has halted sales of the ANCA-associated vasculitis drug Tavneos, following an earlier move by the European Medicines Agency, while UniQure (QURE) — trading at 46.44, down 2.97% on the day as of 15:21 GMT on 2 September 2026 — has filed for approval of its Huntington's disease gene therapy.

Two regulatory events pulled biotech investors in opposite directions on Wednesday. In London, the Medicines and Healthcare products Regulatory Agency halted sales of Tavneos, the treatment for ANCA-associated vasculitis, following the lead already taken by the European Medicines Agency. And in the United States, UniQure (QURE) confirmed it has begun seeking approval for its gene therapy in Huntington's disease — the most closely watched programme in the company's portfolio and, for many holders, the entire investment case.

The market reaction was measured rather than dramatic. UniQure changed hands at 46.44, down 2.97% on the day from a previous close of 47.86, as of the last trade at 15:21 GMT on 2 September 2026. The stock had traded as high as 50.98 during the session before giving that ground back — a day range of 46.02 to 50.98 that shows how much disagreement there is about what a filing, on its own, is worth.

A second regulator closes the door on Tavneos

The significant word in the MHRA's action is "followed." When one major agency suspends a product and a second falls in behind it, the pattern tends to run one way: other regulators reviewing the same dossier are unlikely to reach a materially friendlier conclusion. National health systems that had the drug on formulary now have to move patients, and prescribers who built treatment plans around it need alternatives.

ANCA-associated vasculitis is a rare autoimmune disease in which the body's own antibodies attack small blood vessels, damaging the kidneys, lungs and other organs. The therapeutic options are narrow, and standard care has historically leaned on steroids with their well-documented long-term costs. Tavneos was positioned as a way to reduce that steroid burden. Removing it from two of the world's most influential regulatory jurisdictions narrows an already narrow field, and that is the part of the story patients will feel first, whatever the commercial arithmetic.

Amgen (AMGN) — which sits among the large-cap names moving alongside this news — traded at 437.37, off 0.17% from a prior close of 438.12, in a session range of 436.11 to 445.57. The scale of the move underlines a point worth making plainly: a rare-disease product suspension is a serious regulatory and clinical event without necessarily being a serious event for a diversified balance sheet.

Why UniQure's filing is the higher-stakes item

Huntington's disease is inherited, progressive and, to date, untreatable at the level of its cause. A single defective gene produces a toxic protein that destroys neurons over decades, and patients typically know their genetic status long before symptoms appear. Every prior attempt at disease-modifying treatment has failed. That is why a gene therapy filing here carries weight far beyond the sponsor's market capitalisation.

It is also why the share reaction was ambivalent rather than euphoric. Submitting an application is a procedural milestone, not an outcome. The questions that decide the value — how the agency treats the evidence base, whether an advisory committee is convened, what durability data the regulator considers sufficient for a one-time treatment delivered into the brain — are all still open. Buyers who pushed the stock toward 50.98 intraday were paying for the eventual answer; sellers who took it to 46.02 were pricing the wait. As Endpoints News reported, both items landed the same day.

For a company whose fortunes ride on a single programme, that binary quality is the defining feature of the equity. There is no commercial franchise underneath to cushion a setback, and no second product to dilute the upside of success.

The wider tape: one collapse, several quiet gains

Around these two events, the day's other biotech names moved with far less drama — with one violent exception.

• TScan Therapeutics (TCRX) fell to 0.42, down 36.79% from a previous close of 0.67, with a day range of 0.42 to 0.59 — closing the session at the very bottom of its band, the signature of a market with no interest in buying the dip.
• Regeneron (REGN) rose 1.42% to 835.48 from 823.82, ranging between 825.77 and 843.17.
• Novocure (NVCR) added 3.05% to 17.91 from 17.38, the best percentage gain among the larger names on the list.
• BioMarin (BMRN) gained 1.73% to 65.96 from 64.84.
• Ascendis (ASND) edged up 0.47% to 261.48, having touched 267.91 earlier in the day.
• Jazz Pharmaceuticals (JAZZ), whose Ziihera featured in the day's news flow, slipped 0.59% to 242.27 from 243.71.
• AstraZeneca (AZN) was down 0.28% at 162.01 from 162.47.
• Hutchmed (HCM) rose 1.09% to 12.04 from 11.91.

The broad market was firmer. The S&P 500 tracker (SPY) stood at $765.96, up 0.55% from $761.78; the Nasdaq 100 proxy (QQQ) was at $709.22, up 0.22%; and the Dow tracker (DIA) reached $530.79, up 0.58%. Against that backdrop, UniQure's decline and TScan's collapse were company-specific, not sector-wide. Nobody sold biotech on Wednesday; they sold particular biotechs.

What determines the next repricing

The Tavneos suspension is, for practical purposes, a settled fact until a regulator says otherwise. The live question is whether other national agencies outside Europe and the UK now act, and whether prescribing societies revise their treatment guidance. Both are slow processes with limited immediate share-price consequence but real clinical consequence.

The UniQure question resolves faster and matters more to the tape. Watch for confirmation of whether the application is granted an expedited review, whether an advisory committee meeting is scheduled, and any statement on the target action date. Each of those is a discrete catalyst capable of moving a single-asset stock double digits in either direction, and the intraday range on filing day — nearly five points from high to low — is a fair guide to how violently the shares can travel on process news alone.

For the rest of the group, the day looked like ordinary drift, with TScan's 36.79% drop the reminder that in small-cap biotech, the distance between a going concern and a penny stock is one piece of news.

Key facts

• UniQure (QURE): 46.44, -2.97% on the day, as of 15:21 GMT 2 Sep 2026
• Regulatory action: MHRA halted UK sales of Tavneos, following the EMA
• Filing: UniQure seeking approval for its Huntington's disease gene therapy
• Biggest mover: TScan Therapeutics (TCRX) 0.42, -36.79%

Frequently asked questions

What did the MHRA do to Tavneos?

The UK's Medicines and Healthcare products Regulatory Agency halted sales of Tavneos, the treatment for ANCA-associated vasculitis. The action followed the European Medicines Agency, which had moved on the product first. When a second major regulator falls in behind the first, other agencies reviewing the same evidence rarely reach a friendlier conclusion.

What is ANCA-associated vasculitis?

It is a rare autoimmune disease in which the patient's own antibodies attack small blood vessels, damaging organs including the kidneys and lungs. Treatment options are limited and standard care has historically relied heavily on steroids, which carry significant long-term side effects. Tavneos was positioned as a way to reduce that steroid burden.

How did UniQure shares react to the Huntington's filing?

UniQure (QURE) traded at 46.44 as of the last trade at 15:21 GMT on 2 September 2026, down 2.97% from a previous close of 47.86. The stock reached 50.98 intraday before falling back to a low of 46.02, a wide range that reflects genuine disagreement over what a regulatory submission alone is worth.

Why is a Huntington's gene therapy significant?

Huntington's disease is an inherited, progressive neurological condition caused by a single defective gene that produces a toxic protein destroying neurons over decades. No treatment addresses that underlying cause, and prior attempts at disease-modifying therapy have failed. A gene therapy approval would be a first in the field.

Which other biotech stocks moved on the day?

TScan Therapeutics (TCRX) fell 36.79% to 0.42, the day's largest move. Novocure (NVCR) rose 3.05% to 17.91, BioMarin (BMRN) gained 1.73% to 65.96 and Regeneron (REGN) added 1.42% to 835.48. Jazz slipped 0.59% to 242.27 and AstraZeneca eased 0.28% to 162.01.

Was this a sector-wide selloff in biotech?

No. The broad market was higher, with the S&P 500 tracker at $765.96, up 0.55%, the Nasdaq 100 proxy up 0.22% at $709.22 and the Dow tracker up 0.58% at $530.79. The declines in UniQure and TScan were company-specific rather than a reflection of sector sentiment.

Sources

• UK regulator halts sales of Tavneos; UniQure seeks approval for Huntington's gene therapy — Endpoints News

Photo: cottonbro studio · Pexels Licence — source